Status:
UNKNOWN
Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid
Lead Sponsor:
Kjeld Schmiegelow
Collaborating Sponsors:
Danish Cancer Society
Conditions:
Acute Lymphoblastic Leukemia
6-mercaptopurine Therapy
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE4
Brief Summary
Acute lymphoblastic leukemia (ALL) accounts for 30 % of all childhood malignancies. The patients undergo four phases of treatment, finishing with a late maintenance phase in which 6-mercaptopurine and...
Eligibility Criteria
Inclusion
- Childhood acute lymphoblastic leukemia patients, age 0-18 years at diagnosis, treated at the department of pediatrics and adolescent medicine, Rigshospitalet.
- Informed consent
Exclusion
- None
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2018
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01906671
Start Date
June 1 2013
End Date
November 1 2018
Last Update
April 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Juliane Marie Centret, Rigshospitalet
Copenhagen, DK-, Denmark, 2100